Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability-Reference-Cited by-同舟云学术

Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability

Published:2015-12 Issue:24 Volume:23 Page:7650-7660
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Kawada Hatsuo,Ebiike Hirosato,Tsukazaki Masao,Yamamoto Shun,Koyama Kohei,Nakamura Mitsuaki,Morikami Kenji,Yoshinari Kiyoshi,Yoshida Miyuki,Ogawa Kotaro,Shinma Nobuo,Tsukuda Takuo,Ohwada Jun

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference13 articles.

1. Targeting the phosphoinositide 3-kinase pathway in cancer

2. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

3. Mutations in a signalling pathway

4. High Frequency of Mutations of the PIK3CA Gene in Human Cancers

5. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues;Pharmaceuticals;2023-01-30

2. Bicyclic 5-6 Systems: Three Heteroatoms 1:2;Comprehensive Heterocyclic Chemistry IV;2022

3. Novel Bis- and Mono-Pyrrolo[2,3-d]pyrimidine and Purine Derivatives: Synthesis, Computational Analysis and Antiproliferative Evaluation;Molecules;2021-06-01

4. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer;European Journal of Medicinal Chemistry;2019-12

5. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective;Journal of Medicinal Chemistry;2018-12-24